Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma
The prognosis of patients with relapsed and refractory primary central nervous system diffuse large B cell lymphoma (PCNSL) is poor and there is no standard salvage treatment currently available. Gene expression profiling and next-generation sequencing have provided massive amounts of data, revealin...
Gespeichert in:
| Veröffentlicht in: | Hematology (Luxembourg) 2022-12, Vol.27 (1), p.105-112 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 112 |
|---|---|
| container_issue | 1 |
| container_start_page | 105 |
| container_title | Hematology (Luxembourg) |
| container_volume | 27 |
| creator | Zhou, Ying Xu, Xiaohong |
| description | The prognosis of patients with relapsed and refractory primary central nervous system diffuse large B cell lymphoma (PCNSL) is poor and there is no standard salvage treatment currently available. Gene expression profiling and next-generation sequencing have provided massive amounts of data, revealing the pathogenic mechanism of PCNSL and identifying potential mechanisms for therapeutic exploration. Here, we review targeted drugs that may change the current treatment model of PCNSL. |
| doi_str_mv | 10.1080/16078454.2021.2019363 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_35068379</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_4ddf663691af4631a1d9d4833867f0df</doaj_id><sourcerecordid>2622485456</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-d9abf092785f9d3d21e2deecf47a881d9da9c371a8020514d944fad4bdbcefef3</originalsourceid><addsrcrecordid>eNp9kU1vFSEUhonR2Fr9CZpZurktX8PAzqbxo0kTN7rGc-FwpWGGEbg29987471tXLnhkMN73hd4CHnL6CWjml4xRQcte3nJKWfLwoxQ4hk5X_ub9eD5P_sz8qrWe0o5pwN9Sc5ET5UWgzknP67nOUUHLeapy6Gb8KFrUHbY0He-7He1i1NXMMFc0V8VDAVcy-XQzSWOsFSHUyuQlsnyO-9rVw-14dilwzj_zCO8Ji8CpIpvTvWCfP_08dvNl83d18-3N9d3GycH0zbewDZQwwfdB-OF5wy5R3RBDqA188aDcWJgoCmnPZPeSBnAy63fOgwYxAW5Pfr6DPf2dDmbIdq_jVx2FkqLLqGV3gelhDIMglSCwWovtRBaDYH61ev90Wsu-dcea7NjrA5TggmXJ1quOJe6l71apP1R6kqudfmep2hG7QrKPoKyKyh7ArXMvTtF7Lcj-qepRzKL4MNREKeQywgPuSRvGxxSLguDycVqxf8z_gBweKR0</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2622485456</pqid></control><display><type>article</type><title>Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma</title><source>Taylor & Francis Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Zhou, Ying ; Xu, Xiaohong</creator><creatorcontrib>Zhou, Ying ; Xu, Xiaohong</creatorcontrib><description>The prognosis of patients with relapsed and refractory primary central nervous system diffuse large B cell lymphoma (PCNSL) is poor and there is no standard salvage treatment currently available. Gene expression profiling and next-generation sequencing have provided massive amounts of data, revealing the pathogenic mechanism of PCNSL and identifying potential mechanisms for therapeutic exploration. Here, we review targeted drugs that may change the current treatment model of PCNSL.</description><identifier>ISSN: 1607-8454</identifier><identifier>EISSN: 1607-8454</identifier><identifier>DOI: 10.1080/16078454.2021.2019363</identifier><identifier>PMID: 35068379</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Animals ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; BTK inhibitors ; Central Nervous System Neoplasms - drug therapy ; Drug Discovery ; Humans ; immune checkpoint inhibitors ; Immune Checkpoint Inhibitors - pharmacology ; Immune Checkpoint Inhibitors - therapeutic use ; immunomodulators ; Lymphoma, Large B-Cell, Diffuse - drug therapy ; Molecular Targeted Therapy ; Neoplasm Recurrence, Local - drug therapy ; PCNSL ; PI3 K/mTOR inhibitors ; Prognosis ; Protein Kinase Inhibitors - pharmacology ; Protein Kinase Inhibitors - therapeutic use ; relapsed and refractory</subject><ispartof>Hematology (Luxembourg), 2022-12, Vol.27 (1), p.105-112</ispartof><rights>2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-d9abf092785f9d3d21e2deecf47a881d9da9c371a8020514d944fad4bdbcefef3</citedby><cites>FETCH-LOGICAL-c479t-d9abf092785f9d3d21e2deecf47a881d9da9c371a8020514d944fad4bdbcefef3</cites><orcidid>0000-0001-9619-0651</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/16078454.2021.2019363$$EPDF$$P50$$Ginformaworld$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/16078454.2021.2019363$$EHTML$$P50$$Ginformaworld$$Hfree_for_read</linktohtml><link.rule.ids>314,777,781,861,2096,27483,27905,27906,59122,59123</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35068379$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhou, Ying</creatorcontrib><creatorcontrib>Xu, Xiaohong</creatorcontrib><title>Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma</title><title>Hematology (Luxembourg)</title><addtitle>Hematology</addtitle><description>The prognosis of patients with relapsed and refractory primary central nervous system diffuse large B cell lymphoma (PCNSL) is poor and there is no standard salvage treatment currently available. Gene expression profiling and next-generation sequencing have provided massive amounts of data, revealing the pathogenic mechanism of PCNSL and identifying potential mechanisms for therapeutic exploration. Here, we review targeted drugs that may change the current treatment model of PCNSL.</description><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>BTK inhibitors</subject><subject>Central Nervous System Neoplasms - drug therapy</subject><subject>Drug Discovery</subject><subject>Humans</subject><subject>immune checkpoint inhibitors</subject><subject>Immune Checkpoint Inhibitors - pharmacology</subject><subject>Immune Checkpoint Inhibitors - therapeutic use</subject><subject>immunomodulators</subject><subject>Lymphoma, Large B-Cell, Diffuse - drug therapy</subject><subject>Molecular Targeted Therapy</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>PCNSL</subject><subject>PI3 K/mTOR inhibitors</subject><subject>Prognosis</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>relapsed and refractory</subject><issn>1607-8454</issn><issn>1607-8454</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9kU1vFSEUhonR2Fr9CZpZurktX8PAzqbxo0kTN7rGc-FwpWGGEbg29987471tXLnhkMN73hd4CHnL6CWjml4xRQcte3nJKWfLwoxQ4hk5X_ub9eD5P_sz8qrWe0o5pwN9Sc5ET5UWgzknP67nOUUHLeapy6Gb8KFrUHbY0He-7He1i1NXMMFc0V8VDAVcy-XQzSWOsFSHUyuQlsnyO-9rVw-14dilwzj_zCO8Ji8CpIpvTvWCfP_08dvNl83d18-3N9d3GycH0zbewDZQwwfdB-OF5wy5R3RBDqA188aDcWJgoCmnPZPeSBnAy63fOgwYxAW5Pfr6DPf2dDmbIdq_jVx2FkqLLqGV3gelhDIMglSCwWovtRBaDYH61ev90Wsu-dcea7NjrA5TggmXJ1quOJe6l71apP1R6kqudfmep2hG7QrKPoKyKyh7ArXMvTtF7Lcj-qepRzKL4MNREKeQywgPuSRvGxxSLguDycVqxf8z_gBweKR0</recordid><startdate>20221231</startdate><enddate>20221231</enddate><creator>Zhou, Ying</creator><creator>Xu, Xiaohong</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-9619-0651</orcidid></search><sort><creationdate>20221231</creationdate><title>Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma</title><author>Zhou, Ying ; Xu, Xiaohong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-d9abf092785f9d3d21e2deecf47a881d9da9c371a8020514d944fad4bdbcefef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>BTK inhibitors</topic><topic>Central Nervous System Neoplasms - drug therapy</topic><topic>Drug Discovery</topic><topic>Humans</topic><topic>immune checkpoint inhibitors</topic><topic>Immune Checkpoint Inhibitors - pharmacology</topic><topic>Immune Checkpoint Inhibitors - therapeutic use</topic><topic>immunomodulators</topic><topic>Lymphoma, Large B-Cell, Diffuse - drug therapy</topic><topic>Molecular Targeted Therapy</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>PCNSL</topic><topic>PI3 K/mTOR inhibitors</topic><topic>Prognosis</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>relapsed and refractory</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhou, Ying</creatorcontrib><creatorcontrib>Xu, Xiaohong</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Hematology (Luxembourg)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhou, Ying</au><au>Xu, Xiaohong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma</atitle><jtitle>Hematology (Luxembourg)</jtitle><addtitle>Hematology</addtitle><date>2022-12-31</date><risdate>2022</risdate><volume>27</volume><issue>1</issue><spage>105</spage><epage>112</epage><pages>105-112</pages><issn>1607-8454</issn><eissn>1607-8454</eissn><abstract>The prognosis of patients with relapsed and refractory primary central nervous system diffuse large B cell lymphoma (PCNSL) is poor and there is no standard salvage treatment currently available. Gene expression profiling and next-generation sequencing have provided massive amounts of data, revealing the pathogenic mechanism of PCNSL and identifying potential mechanisms for therapeutic exploration. Here, we review targeted drugs that may change the current treatment model of PCNSL.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>35068379</pmid><doi>10.1080/16078454.2021.2019363</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-9619-0651</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1607-8454 |
| ispartof | Hematology (Luxembourg), 2022-12, Vol.27 (1), p.105-112 |
| issn | 1607-8454 1607-8454 |
| language | eng |
| recordid | cdi_pubmed_primary_35068379 |
| source | Taylor & Francis Open Access; MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use BTK inhibitors Central Nervous System Neoplasms - drug therapy Drug Discovery Humans immune checkpoint inhibitors Immune Checkpoint Inhibitors - pharmacology Immune Checkpoint Inhibitors - therapeutic use immunomodulators Lymphoma, Large B-Cell, Diffuse - drug therapy Molecular Targeted Therapy Neoplasm Recurrence, Local - drug therapy PCNSL PI3 K/mTOR inhibitors Prognosis Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use relapsed and refractory |
| title | Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T08%3A58%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Application%20of%20new%20targeted%20drugs%20in%20relapsed/refractory%20primary%20central%20nervous%20system%20lymphoma&rft.jtitle=Hematology%20(Luxembourg)&rft.au=Zhou,%20Ying&rft.date=2022-12-31&rft.volume=27&rft.issue=1&rft.spage=105&rft.epage=112&rft.pages=105-112&rft.issn=1607-8454&rft.eissn=1607-8454&rft_id=info:doi/10.1080/16078454.2021.2019363&rft_dat=%3Cproquest_pubme%3E2622485456%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2622485456&rft_id=info:pmid/35068379&rft_doaj_id=oai_doaj_org_article_4ddf663691af4631a1d9d4833867f0df&rfr_iscdi=true |